Tags

Type your tag names separated by a space and hit enter

The renin-angiotensin-aldosterone system and heart failure.
Cardiol Clin. 2014 Feb; 32(1):21-32, vii.CC

Abstract

The renin-angiotensin-aldosterone system (RAAS) plays a critical role in the pathophysiology of heart failure with reduced ejection fraction (HFrEF). Targeting components of the RAAS has produced significant improvements in morbidity and mortality. Angiotensin-converting enzyme (ACE) inhibitors remain first-line therapy for all patients with a reduced ejection fraction. Angiotensin-receptor blockers may be used instead of ACE inhibitors in patients with intolerance, or in conjunction with ACE inhibitors to further reduce symptoms. Recent data support broader indications for aldosterone antagonists in heart failure, and the combination of an ACE-inhibitor and aldosterone antagonist has become the preferred strategy for dual blockade of the RAAS.

Authors+Show Affiliations

Center for Heart Transplant and Assist Devices, Advocate Christ Medical Center, 4400 West 95th Street, Suite 407, Oak Lawn, IL 60453, USA; University of Illinois at Chicago College of Medicine, Chicago, IL 60612, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

24286576

Citation

Sayer, Gabriel, and Geetha Bhat. "The Renin-angiotensin-aldosterone System and Heart Failure." Cardiology Clinics, vol. 32, no. 1, 2014, pp. 21-32, vii.
Sayer G, Bhat G. The renin-angiotensin-aldosterone system and heart failure. Cardiol Clin. 2014;32(1):21-32, vii.
Sayer, G., & Bhat, G. (2014). The renin-angiotensin-aldosterone system and heart failure. Cardiology Clinics, 32(1), 21-32, vii. https://doi.org/10.1016/j.ccl.2013.09.002
Sayer G, Bhat G. The Renin-angiotensin-aldosterone System and Heart Failure. Cardiol Clin. 2014;32(1):21-32, vii. PubMed PMID: 24286576.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The renin-angiotensin-aldosterone system and heart failure. AU - Sayer,Gabriel, AU - Bhat,Geetha, PY - 2013/11/30/entrez PY - 2013/11/30/pubmed PY - 2014/7/24/medline KW - Aldosterone KW - Angiotensin II KW - Angiotensin-converting enzyme inhibitors KW - Angiotensin-receptor blockers KW - Heart failure KW - Neurohormonal KW - Renin-angiotensin-aldosterone system SP - 21-32, vii JF - Cardiology clinics JO - Cardiol Clin VL - 32 IS - 1 N2 - The renin-angiotensin-aldosterone system (RAAS) plays a critical role in the pathophysiology of heart failure with reduced ejection fraction (HFrEF). Targeting components of the RAAS has produced significant improvements in morbidity and mortality. Angiotensin-converting enzyme (ACE) inhibitors remain first-line therapy for all patients with a reduced ejection fraction. Angiotensin-receptor blockers may be used instead of ACE inhibitors in patients with intolerance, or in conjunction with ACE inhibitors to further reduce symptoms. Recent data support broader indications for aldosterone antagonists in heart failure, and the combination of an ACE-inhibitor and aldosterone antagonist has become the preferred strategy for dual blockade of the RAAS. SN - 1558-2264 UR - https://www.unboundmedicine.com/medline/citation/24286576/The_renin_angiotensin_aldosterone_system_and_heart_failure_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0733-8651(13)00085-4 DB - PRIME DP - Unbound Medicine ER -